• Explore /
  • Poster
  • / A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.

A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.

Abstract Poster

Authors

Bob Li

Bob T. Li

Memorial Sloan Kettering Cancer Center, New York, NY

Bob T. Li , Mark D. Pegram , Keun-Wook Lee , Manish Sharma , Jeeyun Lee , Alexander I. Spira , Glenn J. Hanna , Yoon-Koo Kang , Drew W. Rasco , Kathleen N. Moore , Benjamin Adam Weinberg , Michael N. Alonso , Jason Ptacek , Ming Yin , Coya Tapia , Lu Xu , Edith A. Perez , Ecaterina Elena Dumbrava

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Cellular Immmunotherapy

Clinical Trial Registration Number

NCT04278144

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2538)

DOI

10.1200/JCO.2023.41.16_suppl.2538

Abstract #

2538

Poster Bd #

380

Abstract Disclosures

Similar Posters

First Author: Manish Sharma

First Author: Neil Howard Segal

First Author: Neil Howard Segal

First Author: Kevin Joseph Harrington